Equities Analysts Offer Predictions for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Harmony Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of $3.71 for the year. Cantor Fitzgerald has a "Overweight" rating and a $58.00 price target on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analysts' expectations of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's quarterly revenue was up 16.0% compared to the same quarter last year. During the same period last year, the business earned $0.63 earnings per share.

A number of other research firms have also recently issued reports on HRMY. Oppenheimer reaffirmed an "outperform" rating and issued a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Harmony Biosciences in a research note on Thursday, January 16th. Raymond James reiterated an "outperform" rating and set a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Mizuho upped their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Finally, Needham & Company LLC restated a "buy" rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and an average target price of $55.00.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY traded down $1.62 during midday trading on Wednesday, reaching $38.84. 295,817 shares of the company traded hands, compared to its average volume of 538,446. The firm has a market cap of $2.22 billion, a PE ratio of 18.42, a PEG ratio of 0.54 and a beta of 0.78. The stock's 50-day simple moving average is $34.46 and its 200-day simple moving average is $34.96. Harmony Biosciences has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 33,126 shares of company stock valued at $1,303,727 over the last 90 days. Company insiders own 30.80% of the company's stock.

Institutional Investors Weigh In On Harmony Biosciences

A number of hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its position in shares of Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company's stock valued at $28,871,000 after buying an additional 112,197 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock valued at $26,416,000 after buying an additional 140,690 shares during the last quarter. Millennium Management LLC boosted its position in shares of Harmony Biosciences by 51.6% during the second quarter. Millennium Management LLC now owns 307,420 shares of the company's stock valued at $9,275,000 after buying an additional 104,691 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Harmony Biosciences by 145.4% during the second quarter. Marshall Wace LLP now owns 305,612 shares of the company's stock valued at $9,220,000 after buying an additional 181,092 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.